KPV dosage: what has been published
Topical and oral: the two routes the 2026 HHS policy lists.
There is no published human dose for KPV. The doses in the research come from mouse colitis studies, given by mouth, and cannot be converted into a dose for people. KPV is not FDA-approved, and REMEVi does not currently offer it. Published protocols vary; a licensed provider sets your dose; never self-dose.
KPV is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.
REMEVi does not currently offer KPV.
Published KPV doses by route
| Route | Published amount and frequency | Who was studied | Source |
|---|---|---|---|
| Oral | KPV 100 µM in drinking water | Mice with chemically induced colitis (animal data) | Dalmasso et al., Gastroenterology 2008 |
| Oral | 16 µg/kg per day by oral gavage, inside nanoparticles in a hydrogel | Mice with chemically induced colitis, five per group (animal data) | Xiao et al., Molecular Therapy 2017 |
| Oral (people) | No published human dose found (checked 2026-11-02) | — | PubMed search |
| Topical | Dose not stated in the abstract; a mouse ear-swelling model | Mice (animal data) | Hiltz & Lipton, FASEB Journal 1989 |
| Topical (people) | No published human dose found (checked 2026-11-02) | — | PubMed search |
Published protocols vary; a licensed provider sets your dose; never self-dose. A mouse dose measured per kilogram, or as a concentration in drinking water, does not translate into a human dose by simple arithmetic, and we do not convert it.
Why published KPV dosage charts differ
KPV dosage charts online rarely trace back to a human study, because none has been published. They differ for a few reasons:
- They are built from mouse studies that used different delivery methods: plain KPV in water, or KPV packed into nanoparticles that release in the colon.
- Some charts list injection doses, but injection is not a route the 2026 policy covers for KPV.
- Charts may describe a modified molecule sold under a similar name rather than KPV acetate, the form the policy names.
- Oral absorption of a small peptide is uncertain, which is why the policy asks for human bioavailability documentation for oral products.
Who sets a KPV dose
Under the HHS policy, KPV is compounded on a patient-specific prescription. The licensed prescriber decides whether KPV fits you, which route, how much and how often, and the 503A pharmacy prepares that product. A dose from a forum or vendor chart is not a prescription.
More questions
What is the KPV dosage?
There is no published human dose for KPV. The doses in the research come from mouse colitis studies, given by mouth, and cannot be converted into a dose for people. KPV is not FDA-approved, and REMEVi does not currently offer it. Published protocols vary; a licensed provider sets your dose; never self-dose.
Sources
- Dalmasso et al., Gastroenterology 2008 — PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (read November 2, 2026)
- Xiao et al., Molecular Therapy 2017 — Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis (read November 2, 2026)
- Hiltz & Lipton, FASEB Journal 1989 — Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH (read November 2, 2026)
- HHS, Federal Register — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526, October 30, 2026) (read November 2, 2026)
- Holtz, Beaver & Rosen (Foley & Lardner), National Law Review, Oct 30, 2026 — HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides (read November 2, 2026)
- Bigica, Nutritional Outlook, Nov 2, 2026 — What the Interim Compounding Pathway for Peptides Could Mean for Supplement Brands (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·